Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin)

Cell experiment:

PEL cells are incubated in triplicate in a 96-well microculture plate in the presence of different concentrations of methyl-β-cyclodextrin (0-10 mM) in a final volume of 0.1 mL for 24 h at 37°C. Subsequently, MTT (0.5 mg/mL final concentration) is added to each well. After 3 h of additional incubation, 100 μL of a 0.04 N HCl is added to dissolve the crystals. Absorption values at 570 nm are determined[1].

Animal experiment:

Mice: Female NRJ mice are intraperitoneally inoculated with BCBL-1 cells suspended in PBS. The mice are then treated with intraperitoneal injections of PBS or methyl-β-cyclodextrin (500 mg/kg per day). Tumor burdens are evaluated by measuring body weights and ascites[1].

References:

[1]. Mundhara N, et al. Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents. Sci Rep. 2019 May 21;9(1):7638.
[2]. Chen X, et al. Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. J Biol Chem. 2002 Dec 20;277(51):49631-7.
[3]. Gotoh K, et al. The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts. Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):285-9.
[4]. Tiwari G, et al. Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci. 2010 Apr;2(2):72-9.